Tofacitinib (CP-690550)

Licensed by Pfizer Catalog No.S2789 Synonyms: Tasocitinib

For research use only.

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.

Tofacitinib (CP-690550) Chemical Structure

CAS No. 477600-75-2

Selleck's Tofacitinib (CP-690550) has been cited by 130 publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Other JAK Products

Biological Activity

Description Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
Targets
JAK3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
JAK1 [1]
(Cell-free assay)
1 nM 20 nM 112 nM
In vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. [1] CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). [2] CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. [3] A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cells NXzTb4R4TnWwY4Tpc44hSXO|YYm= MormNE4yNzBwMz:xJO69VQ>? MnvjNlQhcA>? M4HCbIRqe3K3cITzJO6{[y2laHHpckBkgXSxa3nu[UB{cWewYXzpcoc> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN6M{K0NUc,OjF|OEOyOFE9N2F-
CD4+ T  MlTqSpVv[3Srb36gRZN{[Xl? NITzOHYyODBibl2= M{P2e|I1NzR6IHi= MUXhZpJw\2G2ZYOgR2Q{NWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKFOWQWTz NUXESZFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFQ2QDBpPkKxPFg1PThyPD;hQi=>
CD4+ T  M3LIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnuT2EyOTByL{WwNEBvVQ>? M{DRVVQ5KGh? MlHrbY5pcWKrdIOgZY51cS2FREOtbY5lfWOnZDDDSFQsyqCWIHPlcIwheHKxbHnm[ZJifGmxbh?= NYDLeXh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFQ2QDBpPkKxPFg1PThyPD;hQi=>
CD4+ T  MXfGeY5kfGmxbjDBd5NigQ>? MWeyNE8yODBxNUCwJI5O NFXERms1QCCq M2DaPYlvcGmkaYTzJJRp\SCuZY\lcJMhd2ZiIFnMMVQtKEmITj5Ot{whUUxvMUfBJIFv\CCLTD2yNi=> M364eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi0OVgxLz5{MUi4OFU5ODxxYU6=
Sf9 NGjDXlBHfW6ldHnvckBie3OjeR?= MV2zNEBucW6| MmjXTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvZoXz[YQhUkGNMzDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcocheG:ueXfseZRidWmlIHHjbYQufHm{b4PpcoUh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEurIE2gNE4xODB2IN88UU4> NWq2S281RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9 NVX5c21OTnWwY4Tpc44h[XO|YYm= M1v2eVkxKG2rboO= M2DqTWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiTj30[ZJucW6jbDDHV3QufGGpZ3XkJGpCUzNiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{B2e2mwZzDCbY91cW5vTFOtSXFGTEWSRVfEXWZGX0yHIHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSByLkCwNFYh|ryPLh?= NEDQZnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
Sf9 NELFfJlHfW6ldHnvckBie3OjeR?= M{[wVlMxKG2rboO= MXnJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC2odYPl[EBLSUtzIHPheIFtgXSrYzDkc41icW5iZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyC3c3nu[{Bxd2y7Z3z1eIFucWNiYXPp[E11gXKxc3nu[UBieyC|dXLzeJJifGViYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhU2liPTCwMlAxODdizszNMi=> NUXsTIZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9 M3jsRmZ2dmO2aX;uJIF{e2G7 NGLwV3I{OCCvaX7z M3\Wd2lvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLX\1d4VlKEqDS{KgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKHCxbInncJV1[W2rYzDhZ4llNXS7cn;zbY5mKGG|IIP1ZpN1emG2ZTDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCNaTC9JFAvODByNzFOwG0v NYLUXmZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9 MV;GeY5kfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEeVVD30ZYdo\WRiSlixJIRwdWGrbjCoO|g2KHSxMUGyOUkhd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMECxJO69VS5? NVTJSYZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
Sf9 M4OyR2Z2dmO2aX;uJIF{e2G7 MXXJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiaIXtZY4hUkGNMzDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[nliRVzJV2EtKEmFNUCgQUAxNjByMTFOwG0v NELzVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
Sf9 MVfGeY5kfGmxbjDhd5NigQ>? M1faPFkxKG2rboO= MXfJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiR2PUMZRi\2enZDDKRWsyKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiQnnveIlvNUyFLVXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDUVk1HWkWWIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB6N{e1NEc,OjJyOEe3OVA9N2F-
Sf9 Mk\rSpVv[3Srb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiaIXtZY4hUkGNMzDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[nliRVzJV2EtKEmFNUCgQUAxNjByM{Og{txONg>? NFmzdHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
Sf9 M3fyNmZ2dmO2aX;uJIF{e2G7 M1S0UlkxKG2rboO= NUT1WJBWUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDOMZRmem2rbnHsJGdUXC22YXfn[YQhUkGNMjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJGJqd3Srbj3MR{1GWUWGRWDFS2R[TkWZTFWgZZMhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IECuNFA1KM7:TT6= M{W1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
SF21 MYrGeY5kfGmxbjDhd5NigQ>? MWSxNEBucW6| NYHiVoZZUW6qaXLpeIlwdiCxZjDKRWszKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPGNlEh[2WubIOgeZNqdmdiQnnveIlvNUuDSVXUSGtGYVmWVlvEJIF{KHO3YoP0doF1\SCjbnSgX|M{WGejbX3hYWFVWCCrbnP1ZoF1\WRiZn;yJFExKG2rboOgdJJqd3JidH:gd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgWI9x[2:3boSgZY5idHm|aYOsJGlEPTBiPTCwMlAxPCEQvF2u M37hbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUSxOlcxLz5{M{W0NVY4ODxxYU6=
insect cells MXHGeY5kfGmxbjDhd5NigQ>? NXfTNZBKUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJGpiczFiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{A4OCC3TTDBWHAtKEmFNUCgQUAxNjByNkGg{txONg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
insect cells MYTGeY5kfGmxbjDhd5NigQ>? NUXxW29QUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJGpiczNiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{AyQCC3TTDBWHAtKEmFNUCgQUAxNjByODFOwG0v NHH0e409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
T-cells M2\oT2Z2dmO2aX;uJIF{e2G7 MYW3NkBpenN? NHS3T5VKdmirYnn0bY9vKG:oIFnMNk1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iVDDj[YxteyCjc4Pld5Nm\CCjczDbN2hefGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjBzMTFOwG0v M4jkNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
insect cells M2XnOGZ2dmO2aX;uJIF{e2G7 NGrxW2tKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgToFsOiCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW|aX7nJFIxKHWPIFHUVEwhUUN3MDC9JFAvODF{IN88UU4> NEPKRo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
MO7 NIrsdm9HfW6ldHnvckBie3OjeR?= NXj3bWNWUW6qaXLpeIlwdiCxZjDKZYs{NW2nZHnheIVlKEmOMUWtbY5lfWOnZDDTeIF1PSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVU95IHPlcIx{KGK7IHPlcIwu[mG|ZXSgZZN{[XluIFnDOVAhRSByLkCyOEDPxE1w MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
Ba/F3 MWTGeY5kfGmxbjDhd5NigQ>? NXLWNHN4PjBibXnudy=> NXTGeG1[UW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgTmFMOSCneIDy[ZN{\WRiaX6gRoEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDBwMEK2JO69VS5? MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
T-cells NG\Ue|hHfW6ldHnvckBie3OjeR?= NFPa[YpKdmirYnn0bY9vKG:oIFrBT|MwOSCrbjDoeY1idiCWIHPlcIx{KGW6cILld5NqdmdiQ1SzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNXO2aX31cIF1\WRiU2TBWFViKHCqb4PwbI9zgWyjdHnvckwhUUN3MDC9JFAvODJ6IN88UU4> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2ME[0PEc,OjN3NEC2OFg9N2F-
PBMC M1fVNWZ2dmO2aX;uJIF{e2G7 NF\SO4ZKdmirYnn0bY9vKEmOLUetbY5l[3WnZDDTWGFVPSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hWEKPQzDj[YxteyCkeTDmcI94KGO7dH;t[ZRzgSxiSVO1NEA:KDBwMEO5JO69VS5? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{N{SyN{c,OjZ7Mke0NlM9N2F-
TF1 NWqzSJpmTnWwY4Tpc44h[XO|YYm= MXmyNEBucW6| MnPFTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNPi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh\m:ubH;3[YQh[nliSVy2JINp[WyuZX7n[UBnd3JiM{CgcYlveyCrbjDwdoV{\W6lZTDv[kB4cG:uZTDicI9w\CxiRVO1NEA:KDBwMESzJO69VS5? NFrGeVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1PVIyPCd-MkO2OVkzOTR:L3G+
TF1 MXTGeY5kfGmxbjDhd5NigQ>? MVTJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNPi2|dHnteYxifGWmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBjgSCDbIDoZXNkemWnbjDhd5NigSxiSV7IJF0hOC5yNEWg{txONg>? Ml3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|N{K2OVMoRjJ4M{eyOlU{RC:jPh?=
CTLL NELYV2tHfW6ldHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKEqja{OtcYVlcWG2ZXSgTWwzNWmwZIXj[YQhW3SjdEWgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIFPUUGwh[2WubIOgZpkh[2WubD3iZZNm\CCjc4PhfUwhUUN3MDC9JFAvODR6IN88UU4> MmOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW2NFUoRjJzMUW1OlA2RC:jPh?=
Sf9 NVrSenJlTnWwY4Tpc44h[XO|YYm= MoTrPVAhdWmwcx?= NVvM[pg{UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDOMZRmem2rbnHsJGdUXC22YXfn[YQhXFmNMjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJGJqd3Srbj3MR{1GWUWGRWDFS2R[TkWZTFWgZZMhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IECuNFUzKM7:TT6= NH7MT4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
TF1 NEjvU4NHfW6ldHnvckBie3OjeR?= MmK1TY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNOi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjygSWM2OCB;IECuNFU{KM7:TT6= Ml7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OUG0NFIoRjJ{NUmxOFAzRC:jPh?=
TF1 M1\POmZ2dmO2aX;uJIF{e2G7 M{[z[VIxKG2rboO= NXLVflBsUW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNicILpc5IhfG9iSVy2MYlv\HWldHnvckBu\WG|dYLl[EBi\nSncjCzNEB1dyB2NTDtbY5{NCCHQ{WwJF0hOC5yNUOg{txONg>? NX3sTHpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVgxQDRpPkKyOlk5ODh2PD;hQi=>
TF1 NEO4fnVHfW6ldHnvckBie3OjeR?= NVfTfFV7OjBibXnudy=> NYPoTpNlUW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWw3KGOqYXzs[Y5o\SCob4KgN|AhdWmwczygSWM2OCB;IECuNFU{KM7:TT6= NU[xcWZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
Ba/F3 MVnGeY5kfGmxbjDhd5NigQ>? NGriVWs3OCCvaX7z NV7ueFhCUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgTmFMOyCneIDy[ZN{\WRiaX6gRoEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDBwMEW0JO69VS5? NWjYWpptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
T-cells M{j6SmZ2dmO2aX;uJIF{e2G7 NUTHUoh2UW6qaXLpeIlwdiCxZjDhcIxw\2WwaXOgZ4VtdHNvc4TpcZVt[XSnZDDwdo9tcW[ncnH0bY9vKGmwIH3vcotmgSCWIHPlcIx{KGK7IH3pfIVlKGy7bYDoc4N6fGVicnXhZ5Rqd25ibXX0bI9lNCCLQ{WwJF0hOC5yNUeg{txONg>? NXjFSo1ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
CD34+ NUjRV3hSTnWwY4Tpc44h[XO|YYm= NVTKTWFkUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKEOGM{SrJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRWDPMY1m\GmjdHXkJINmdGxicILvcIln\XKjdHnvckwhUUN3MDC9JFAvODdzIN88UU4> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{N{SyN{c,OjZ7Mke0NlM9N2F-
TF1 NXu4[mVRTnWwY4Tpc44h[XO|YYm= NGXkfGFKdmirYnn0bY9vKG:oIFnMOE1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gWGYyKGOnbHzzMEBKSzVyIE2gNE4xQCEQvF2u MkLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7M{S0OVcoRjF4OUO0OFU4RC:jPh?=
T-cells NU\yXGlDTnWwY4Tpc44h[XO|YYm= NFPX[5NKdmirYnn0bY9vKG:oIHHscI9o\W6rYzDj[Yxtey2|dHnteYxifGWmIIDyc4xq\mW{YYTpc44hcW5iaIXtZY4hXCClZXzsd{BjgSCvaYjl[EBtgW2yaH;jfZRmKHKnYXP0bY9vKG2ndHjv[EwhUUN3MDC9JFAvODh5IN88UU4> M3OxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
TF1 NEfnSVRHfW6ldHnvckBie3OjeR?= MnfzNlAhdWmwcx?= M4LjfGlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBVTjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBGWE9vaX7keYNm\CCVVFHUOUBxcG:|cHjvdplt[XSrb36gbY5kfWKjdHXkJIZweiB{MDDtbY5{KHC{aX;yJJRwKEWSTz3pcoR2[3Srb36gcYVie3W{ZXSgZYZ1\XJiM{CgeI8hPDVibXnud{whTUN3MDC9JFAvODl|IN88UU4> NWnlNYJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVgxQDRpPkKyOlk5ODh2PD;hQi=>
TF1 Ml3xSpVv[3Srb36gZZN{[Xl? MYSyNEBucW6| NUHLcHFiUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWSTz3pcoR2[2WmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWw3KGOqYXzs[Y5o\SCob4KgN|AhdWmwczygSWM2OCB;IECuNFk{KM7:TT6= M{jzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
PBMC M1K3RmZ2dmO2aX;uJIF{e2G7 NGLrcZZKdmirYnn0bY9vKG:oIFrBT|EhcW5iaIXtZY4hWEKPQzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLU[tbY5lfWOnZDDNR3AyKHOnY4LleIlwdixiSVO1NEA:KDBwMEm1JO69VS5? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{N{SyN{c,OjZ7Mke0NlM9N2F-
TF1 NXPlOXRSTnWwY4Tpc44h[XO|YYm= M2TmXlIhcHK| NIrYepBKdmirYnn0bY9vKG:oIFrBT|IhcW5iR13DV2Yue3SrbYXsZZRm\CCqdX3hckBVTjFiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliR13DV2Yhe3SrbYXsZZRqd25iZn;yJFUxKG2rboOgZpkhTkGFUzDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkC5OUDPxE1w NE\vXWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNFM2QSd-MkexN|A{PTl:L3G+
TF1 MVjGeY5kfGmxbjDhd5NigQ>? MnWwTY5pcWKrdHnvckBw\iCMQVuyJIlvKEWSTz3zeIlufWyjdHXkJIh2dWGwIGTGNUBk\WyuczDlfJBz\XO|aX7nJJN1[WKueTDpcpRm\3KjdHXkJIJmfGFvbHHjeIFu[XOnIILldI9zfGW{IHflcoUhfW6mZYKgZ49vfHKxbDDv[kBUXEGWNTDy[ZNxd26|ZTDlcIVu\W62czDpckBqdnSncn\ldo9vKHKnZ4XsZZRwenliZnHjeI9zKDFiZ3Xu[UBxem:vb4TldkBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkGwO{DPxE1w NXO0N|g1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOVYyOzZpPkK5NVU3OTN4PD;hQi=>
Sf9 NXXGW|FiTnWwY4Tpc44h[XO|YYm= M4PZVGlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDoeY1idiCMQVuxJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMUGg{txONg>? NUnle4ptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNFU4OTFpPkKxNVA2PzFzPD;hQi=>
T-cells Mn\TSpVv[3Srb36gZZN{[Xl? M{[5dWlvcGmkaYTpc44hd2ZiYXzsc4dmdmmlIHPlcIx{NXO2aX31cIF1\WRicILvcIln\XKjdHnvckBqdiCvb4Xz[UBVKGOnbHzzJIJ6KG2reHXkJIx6dXCqb3P5eIUhemWjY4Tpc44hdWW2aH;kMEBKSzVyIE2gNE4yOTVizszNMi=> NGXKRlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
ME180 NXHtNZpWTnWwY4Tpc44h[XO|YYm= NXnYdZBnUW6qaXLpeIlwdiCxZjDKRWsyKGmwIFnMOk1{fGmvdXzheIVlKGi3bXHuJG1GOThyIHPlcIx{KGW6cILld5Nqdmdic4ThZox6KGmwdHXndoF1\WRiYnX0ZU1t[WO2YX3hd4UhemWyb4L0[ZIh\2WwZTD1coRmeiClb370do9tKG:oIIPpd{1qdmS3Y3nicIUh\WynbXXueEBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkGyOEDPxE1w NHPtOoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
CTLL-2 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHvkZ2E4OiCqcoO= NF3lWpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGlNNTJvc4TpcZVt[XSnZDDtc5V{\SCFVFzMMVIh[2WubIOg[ZhxemW|c3nu[{BLSUtzL1rBT|Mh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNE4yOzJizszNMi=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
HT2 M4frZWZ2dmO2aX;uJIF{e2G7 M2G2ZWlvcGmkaYTpc44hd2ZiSlHLN{BqdiCvb4Xz[UBJXDJiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2WubDDndo94fGhuIFnDOVAhRSByLkG1OkDPxE1w M{XKbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{exNVgxLz5{N{e3NVE5ODxxYU6=
DND/L12 NYnKRoUxTnWwY4Tpc44h[XO|YYm= M1mxSFMxKG2rboO= MlPCTY5pcWKrdHnvckBw\iCMQVuzJIlvKGi3bXHuJGRPTC:OMUKgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCudXPp[oVz[XOnIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIh2dWGwIIPldpVuKGGuYoXtbY4tKEmFOUCgQUAxNjF4IN88UU4> NX:5WppCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
T-cells NYXybZNiTnWwY4Tpc44h[XO|YYm= M{fDeGlvcGmkaYTpc44hd2ZiSlHLNk8yKGmwIHj1cYFvKFRiY3XscJMh\XiycnXzd4lv\yCFREOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJSm5o[W2vYT3zeIlufWyjdHXkJHNVSVRzIIDoc5NxcG:{eXzheIlwdixiSVO1NEA:KDBwMUeg{txONg>? NGLWN2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NFY1QCd-MkO1OFA3PDh:L3G+
insect M4rGdGZ2dmO2aX;uJIF{e2G7 MkW3TY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIGT5b|Ih\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{B2e2mwZzCzOUB2VSCDVGCsJGlEPTBiPTCwMlE4PiEQvF2u NGnSSo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
Ba/F3 NUDhfXN[TnWwY4Tpc44h[XO|YYm= NIj4fFk3OCCvaX7z MVjJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCMQVuyJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4zPjVizszNMi=> M3zXcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
TF1 NI\BUXFHfW6ldHnvckBie3OjeR?= NF3WUWVKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKGOnbHyg[5Jwf3SqLDDJR|UxKD1iMD6yO|UyKM7:TT6= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5MUG4NEc,Ojd5N{GxPFA9N2F-
CD34+ NHLpTHNHfW6ldHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKEqDS{KgbI9ud2SrbXXyJIlvKGi3bXHuJGNFOzRtIHPlcIx{KHOyaXvl[EBqdnSxIHj1cYFvKHeqb3zlJIJtd2:mIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRWDPMYlv\HWlZXSgV3RCXC13IIDoc5NxcG:{eXzheIlwdiCycnXpcoN2[mG2ZXSg[o9zKDR3IH3pcpMh\m:ubH;3[YQh[nliRWDPJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEG1JI1qdnNiYomgSmFEWyCjbnHsfZNqeyxiSVO1NEA:KDBwM{CyJO69VS5? M2HWRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVM{Lz5{NESxO|U{OzxxYU6=
HUO3 MUXGeY5kfGmxbjDhd5NigQ>? MlnGOEBl[Xm| MnvjTY5pcWKrdHnvckBw\iCqdX3hckBIVS2FU1[tbY5lfWOnZDDwdo9tcW[ncnH0bY9vKGmwIHj1cYFvKEiXT{OgZ4VtdHNiYYPz[ZN{\WRiYYOgX|NJZXSqeX3p[Ilv\SCrbnPvdpBwemG2aX;uJIFnfGW{IESg[IF6eyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwJF0hOC5|MkSg{txONg>? NV:4WFNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
HU03 M4WzdWZ2dmO2aX;uJIF{e2G7 NVrxb3BRPzJiaILz NHPBdnFKdmirYnn0bY9vKG:oIFfNMWNUTi2rbnT1Z4VlKGi3bXHuJGhWODNiY3XscJMheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5|MkSg{txONg>? NWDxWZptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNFU4OTFpPkKxNVA2PzFzPD;hQi=>
BAF3 NHXt[ohCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NX;Ec4k6PzJiaILz MlGyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQV[zJINmdGy|IHX4dJJme3OrbnegWGVNNUqDS{Ogb4lv[XOnIHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDBwNUeg{txONg>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
T-cells NEHtfJhHfW6ldHnvckBie3OjeR?= Mn6zN{Bl[Xm| MXTJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxZjDJUFIu[WO2aY\heIVlKGGwZDDDSFMh[W6mIFPENlgh[W62aXLv[Jkue3SrbYXsZZRm\CCvb4Xz[UBETDRvcH;zbZRqfmViVDDj[YxteyCjZoTldkA{KGSjeYOgZpkhYFSWIHHzd4F6NCCLQ{WwJF0hOC54MzFOwG0v MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR4MEi0Nkc,OzB2NkC4OFI9N2F-
NK92 NYjuNWxVTnWwY4Tpc44h[XO|YYm= NXn1TWp3OjBibXnudy=> MV7Jcohq[mm2aX;uJI9nKFS\S{KgbY4hcHWvYX6gUms6OiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNOTJvaX7keYNm\CCVVFHUOEBxcG:|cHjvdplt[XSrb36gbY5kfWKjdHXkJIZweiB{MDDtbY5{KG[xbHzve4VlKGK7IFnMNVIh[2ijbHzlcodmKG[xcjC0OUBucW6|LDDFR|UxKD1iMD63NUDPxE1w NV\hRYNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
TF1 NFuxdIdHfW6ldHnvckBie3OjeR?= NVT4PY5mUW6qaXLpeIlwdiCxZjDJUFMucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJHRHOSClZXzsd{whUUN3MDC9JFAvQCEQvF2u MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl|NES1O{c,OTZ7M{S0OVc9N2F-
UT7 Mo[4SpVv[3Srb36gZZN{[Xl? NWTrPIFrUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFWWNzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCHUF:td5RqdXWuYYTl[EBUXEGWNTDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO|YYmsJGlPUCB;IEGuNVIh|ryPLh?= M2PEd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{eyOlU{Lz5{NkO3NlY2OzxxYU6=
Ba/F3 M4S2WmZ2dmO2aX;uJIF{e2G7 M4jaSVYxKG2rboO= MV7Jcohq[mm2aX;uJI9nKFSHTD3meZNm\CCWWVuyJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNU4zKM7:TT6= NYTCXXJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
T-cells NVS3SFB3TnWwY4Tpc44h[XO|YYm= M2fFXVczKGi{cx?= NWS4fnBrUW6qaXLpeIlwdiCxZjDKRWs{KGmwIILheEB{eGynbn;jfZRq[yCWIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBKVC1{LXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzLkKg{txONg>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF|OUW3OUc,OzBzM{m1O|U9N2F-
SZ4 NYSybGZETnWwY4Tpc44h[XO|YYm= NYrmN3ZuUW6qaXLpeIlwdiCxZjDKRWs{KGmwIHj1cYFvKFOcNDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hUUx{LYP0bY12dGG2ZXSgV3RCXDVicHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDmc4xtd3enZDDifUBKVDJic4TpcZVt[XSrb36gZY5lKG2nYYP1doVlKGGodHXyJFE2KG2rboOgZpkhVVOGIHHzd4F6NCCLQ{WwJF0hOS5{MTFOwG0v MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR4MEi0Nkc,OzB2NkC4OFI9N2F-
BAF3 MnzoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MljLO|IhcHK| NVrmOJZmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXEWOLVrBT|Ihc2mwYYPlJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOVc1KM7:TT6= NXix[2RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzhpPkG5O|YzOjN6PD;hQi=>
HEL M4DxfGZ2dmO2aX;uJIF{e2G7 M2\FT|EhcHJ? MV\Jcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGmwIHj1cYFvKEiHTDDj[YxteyCjZoTldkAyKGi{LDDJR|UxKD1iND63NlQh|ryPLh?= NIqyV4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3NVE5OCd-Mke3O|EyQDB:L3G+
Jurkat NUHHd5lCTnWwY4Tpc44h[XO|YYm= MoHJNlQhcHK| Mm\KTY5pcWKrdHnvckBw\iCjboTpMWNFOy:jboTpMWNFOjhvaX7keYNm\CCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBLfXKtYYSgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTC3Mlg1KM7:TT6= NYXqXHZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
YT NITzWlRHfW6ldHnvckBie3OjeR?= MmTnN|AhdmdxbXy= MVnJcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIFrBT|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHlVKGOnbHzzJIF1KDNyIH7nM41tKGK7IHntcZVvd2Kub4T0bY5oKGGwYXz5d4l{ M3OxZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
YT M1vOVWZ2dmO2aX;uJIF{e2G7 NFTFVI8{OCCwZz;tcC=> MofqTY5pcWKrdHnvckBw\iCLTEKtbY5lfWOnZDDTWGFVPUFicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFmWIHPlcIx{KGG2IEOwJI5oN22uIHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| NHvwRZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
YT MmL0SpVv[3Srb36gZZN{[Xl? M2HwclMxKG6pL33s NXm5c4lkUW6qaXLpeIlwdiCxZjDJUFIucW6mdXPl[EBUXEGWNVKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGnUJINmdGy|IHH0JFMxKG6pL33sJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nz MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
NK-cells MlfWTY1ufW6xc4XwdJJme3OrdnWgZZN{[Xl? NXLRSG1KOSC2bzC1JI1oN2up NWO4Vlh6PCC5ZXXrdy=> M{Kz[2ludXWwb4P1dJBz\XO|aY\lJIFkfGm4aYT5JIlvKG6jaY\lJIN6dm:vb3zneZMhdW:wa3X5JIF{e2W|c3XkJIF{KGWoZnXjeEBwdiCFREOtR2QyPitiTlugZ4VtdHNiYYSgNUB1dyB3IH3nM4toNCCybzDmc5IhPCC5ZXXrdy=> M3TqUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
T-cells NYO2PWNZTnWwY4Tpc44h[XO|YYm= MmXrOUB1dyB3MECgcm0> NHOyUGgyKGi{ MkTBTY5pcWKrdHnvckBw\iCLTEKtbY5lfWOnZDDTeIF1PSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hS0R2KzDUJINmdGy|IHH0JFUhfG9iNUCwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91 NHTHRlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC1N|c2Pid-MUmwOVM4PTZ:L3G+
SUM149PT MYXGeY5kfGmxbjDhd5NigQ>? MkHBN{B2VQ>? NHvCWVUyPiCqcoO= MkXGTY5lfWO2aX;uJI9nKFCWUF62JIlvKGi3bXHuJHNWVTF2OWDUJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU2TBWFMheGixc4Doc5J6dGG2aX;uJIF1KDNidV2gZYZ1\XJiMU[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YheGW{dnHuZYRifGV? NWTsbHJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5O|gyOTJpPkK0PVc5OTF{PD;hQi=>
Hs578T M33yVGZ2dmO2aX;uJIF{e2G7 MlKxN{B2VQ>? MWqxOkBpenN? MmX4TY5lfWO2aX;uJI9nKFCWUF62JIlvKGi3bXHuJGh{PTd6VDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEA{KHWPIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJJBmen[jbnHkZZRm NGfmRYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3PFEyOid-MkS5O|gyOTJ:L3G+
T-cells MYHGeY5kfGmxbjDhd5NigQ>? NYXyXmVSPTBidH:gN|AxKG6P MV:xJIhz MVfJcohq[mm2aX;uJI9nKEqDS{GvTmFMOyCrbjDoeY1idiCFRESgdI9{cXSrdnWgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMOE1{fGmvdXzheIVlKFOWQWS2JJBpd3OyaH;yfYxifGmxbjDheEA2OCC2bzCzNFAhdk1icILlbY5kfWKjdHXkJIZweiBzIHjyJIZwdGyxd3XkJIJ6KEmOLUSgd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgN|AhdWmwczDifUBqdW23bn;icI91KGGwYXz5d4l{ NWjH[nZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVIxPjhpPkK5PFUzODZ6PD;hQi=>
T-cells MWnGeY5kfGmxbjDhd5NigQ>? NELE[|U2OCC2bzCzNFAhdk1? M1nMeVEhcHJ? MWPJcohq[mm2aX;uJI9nKEqDS{GvTmFMOyCrbjDoeY1idiCFRESgdI9{cXSrdnWgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMNk1{fGmvdXzheIVlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDheEBVgXJvNkm1JJJme2mmdXWgZZQhPTBidH:gN|AxKG6PIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCLTD2yJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
T-cells M3HJPWZ2dmO2aX;uJIF{e2G7 M4Dsbl4{ODBibl2= NFHreW4yKGi{ NWTyW3lPUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{KvWHlMOiCrbjDoeY1idiCFRESgdI9{cXSrdnWgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMOk1{fGmvdXzheIVlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEA,OzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE03KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= M4rVVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWyNFY5Lz5{OUi1NlA3QDxxYU6=
TALL-1 M1XuO2Z2dmO2aX;uJIF{e2G7 NX7Jb|JrOSC3TR?= NYPQenpWOyCqcoO= NVLHbpBKUW6qaXLpeIlwdiCxZjDKRWs{KGmwIHj1cYFvKFSDTFytNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMMVIhcW6mdXPl[EBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KEmOLUKgbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgbY1ufW6xYnzveJRqdmd? Mlf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
BA/F3 NGrSSFlHfW6ldHnvckBie3OjeR?= NYj6SIp[OzByIH7N MY[zJIhzew>? MnrpTY5pcWKrdHnvckBw\iCMQVuzJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgN|AxKG6PIHHmeIVzKDNiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nz NIi1OJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
OCL-AML5 MUPGeY5kfGmxbjDhd5NigQ>? M2fhb|EhfU1? NG\MbWs{KGi{cx?= NVO2XHJOUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKE:FTD3BUWw2KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gS20uS1OIIHnu[JVk\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjCzJIhzeyCob3zsc5dm\CCkeTDHUU1EW0ZiaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdITpcoc> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
BA/F3 MlzMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXHUXIVUPzJiaILz M3Gx[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BVTUxvSlHLN{Bi\nSncjC3NkBpenNiYomgZ4VtdCC2aYTldkBodG9iYYPzZZk> M{PWN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BA/F3 M{n2bWZ2dmO2aX;uJIF{e2G7 NHrhfmcyKHWP NVL6VGN6OyCqcoO= MU\Jcohq[mm2aX;uJI9nKEqDS{OgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFMhcHK|IH\vcIxwf2WmIHL5JJB2dGymb4fuJJdqfGhic4Ty[ZB1[X[rZHnuJIJm[WS|IHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| MkDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
Huh7 NGi2[XNHfW6ldHnvckBie3OjeR?= NWGzVYNlOTBidV2= MWWzNEBucW6| MXrJcohq[mm2aX;uJI9nKFS7a{KgbY4hcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gTWZP[WyyaHG1MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKHC{ZT3pcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJGlHVmGucHjhOUB{fGmvdXzheIlwdiCob4KgN|AhdWmwczDtbY5{KGK7IHntcZVvd2Kub4T0bY5o NFniW2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE2QSd-Mk[yN|EyPTl:L3G+
Huh7 NIXweolHfW6ldHnvckBie3OjeR?= Mki2NVAhfU1? M1\ScVMxKG2rboO= NVP5UVJwUW6qaXLpeIlwdiCxZjDUfYszKGmwIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKGKjc3HsJIxmfmWuIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCBzMDD1UUBi\nSncjCzNEBucW6|IHL5JIludXWwb3Lsc5R1cW6p MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOVkoRjJ4MkOxNVU6RC:jPh?=
Huh7 MYXGeY5kfGmxbjDhd5NigQ>? NILuZmQyKHWP MUOzNEBucW6| NF7RNHNKdmirYnn0bY9vKG:oIGT5b|IhcW5iaIXtZY4hUHWqNzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhUU[QYXzwbIE2NWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JFEhfU1icILlMYlv[3WkYYTl[EBnd3JiM{CgcYlveyCkZX\vdoUhUU[QYXzwbIE2KHO2aX31cIF1cW:wIH\vdkA{OCCvaX7zJI1qdnNiYomgbY1ufW6xYnzveJRqdmd? NYHBNoR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPTlpPkK2NlMyOTV7PD;hQi=>
Assay
Methods Test Index PMID
Western blot JAK3 / STAT5 / p-STAT5 ; LMP1 / EBNA1 / BZLF1 ; JAK3 / p-JAK3 / STAT3 27732937 26082451
Growth inhibition assay Cell number 27732937
In vivo In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). [1] Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10–30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). [2]

Protocol (from reference)

Kinase Assay:

[1]

  • JAK3 Kinase Assay:

    A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays.

Cell Research:

[1]

  • Cell lines: Human T blasts cell
  • Concentrations: 0-4000 nM
  • Incubation Time: 4 days
  • Method:

    To measure IL-2-dependent proliferation, isolated lymphocytes are resuspended to a cell density of 1-2 × 106/mL in complete RPMI medium (RPMI 1640 containing 10% (w/v) fetal calf serum (FCS), 1%(w/v) penicillin and treptomycin).Phytohemagluttinin (PHA) is added to a final concentration of 10mg/mL, and the culture incubated for 3 days at 37 °C in a humidified 5% (v/v) CO2 incubator to upregulate IL-2R and JAK3 expression. IL-2 (200U/mL), with or without CP-690,550 is then added and the cells are incubated for 72 hours at 37 °C in a humidified 5% (v/v) CO2 incubator, after which 50 mL of 3H-thymidine (5mCi/mL) is added. The plates are incubated for an additional 18 hours, harvested with a 96-well harvester, and counted on a scintillation counter. HUO3 cells are maintained in culture with granulocyte-macrophage colony stimulating factor and human foreskin fibroblasts are maintained in culture with 10% fetal calf serum. CP-690550 is added to freshly plated cells and cultured for 4 days. 3Hthymidine is added during the last 18 hours of the culture period.

  • (Only for Reference)
Animal Research:

[1]

  • Animal Models: DBA/2 and C57/BL6 mice
  • Dosages: 0-136 ng/mL
  • Administration: Administered via osmotic minipump infusion
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 62 mg/mL warmed
(198.48 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 312.37
Formula

C16H20N6O

CAS No. 477600-75-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05082428 Not yet recruiting -- Ulcerative Colitis Pfizer December 1 2021 --
NCT05087589 Recruiting Drug: Tofacitinib Primary Sjögren''s Syndrome Peking University People''s Hospital November 18 2021 Phase 2
NCT04768504 Recruiting Drug: Tofacitinib 10 mg Immune-Mediated Colitis Khashayar Esfahani|Sir Mortimer B. Davis - Jewish General Hospital November 15 2021 Phase 2
NCT04624230 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer August 12 2021 Phase 3
NCT04496960 Recruiting Drug: tofacitinib|Other: Placebo Sjogren''s Syndrome National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) May 18 2021 Phase 1|Phase 2
NCT04424303 Recruiting Drug: Tofacitinib Ulcerative Colitis Pfizer December 7 2020 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I was just wondering what the main differences between S2789 and S5001?

Answer:
S2789(Tofacitinib (CP-690550)) is the base form of S5001 (Tofacitinib (CP-690550) Citrate). The biological activity of these two compounds are same. The S5001 (Tofacitinib (CP-690550) Citrate) is more suitable for oral administration.

Tags: buy Tofacitinib (CP-690550) | Tofacitinib (CP-690550) supplier | purchase Tofacitinib (CP-690550) | Tofacitinib (CP-690550) cost | Tofacitinib (CP-690550) manufacturer | order Tofacitinib (CP-690550) | Tofacitinib (CP-690550) distributor